uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.920 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic myelomonocytic leukemia? | Azacitidine is the only Small molecule therapy approved by the FDA to treat chronic myelomonocytic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic myelomonocytic leukemia" OR LOWER(mesh_heading) = "chronic myelomonocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191919', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130816', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1191981', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000130816', 'approvedSymbol': 'DNMT1', 'approvedName': 'DNA methyltransferase 1', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192043', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000119772', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192105', 'drugName': 'Azacitidine', 'tradeNames_list': "['Azacitidine', 'Onureg', 'Vidaza']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000119772', 'approvedSymbol': 'DNMT3A', 'approvedName': 'DNA methyltransferase 3 alpha', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Myelomonocytic, Chronic', 'efo_term': 'chronic myelomonocytic leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.495 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hutchinson-Gilford progeria syndrome? | Lonafarnib is the only Small molecule therapy approved by the FDA to treat Hutchinson-Gilford progeria syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hutchinson-gilford progeria syndrome" OR LOWER(mesh_heading) = "hutchinson-gilford progeria syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_148908', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168522', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_148927', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168522', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_148946', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168522', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_148965', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000168522', 'approvedSymbol': 'FNTA', 'approvedName': 'farnesyltransferase, CAAX box, alpha', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_148984', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000257365', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_149003', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000257365', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_149022', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000257365', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_149041', 'drugName': 'Lonafarnib', 'tradeNames_list': "['Zokinvy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000257365', 'approvedSymbol': 'FNTB', 'approvedName': 'farnesyltransferase, CAAX box, beta', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Progeria', 'efo_term': 'Hutchinson-Gilford progeria syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.961 | Q16 | What Small molecule therapies have been approved by the FDA to treat coronary atherosclerosis? | Propranolol Hydrochloride is the only Small molecule therapy approved by the FDA to treat coronary atherosclerosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "coronary atherosclerosis" OR LOWER(mesh_heading) = "coronary atherosclerosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937023', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937046', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937069', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}, {'UUID': 'DrugTargetsIndication121923_text_937092', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary atherosclerosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1106 | Q16 | What Small molecule therapies have been approved by the FDA to treat gestational diabetes? | There are no drug Small molecule therapies approved to treat gestational diabetes. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gestational diabetes" OR LOWER(mesh_heading) = "gestational diabetes") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1040 | Q16 | What Small molecule therapies have been approved by the FDA to treat esophageal carcinoma? | There are no drug Small molecule therapies approved to treat esophageal carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "esophageal carcinoma" OR LOWER(mesh_heading) = "esophageal carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.591 | Q16 | What Small molecule therapies have been approved by the FDA to treat Pineoblastoma? | There are no drug Small molecule therapies approved to treat Pineoblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pineoblastoma" OR LOWER(mesh_heading) = "pineoblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.757 | Q16 | What Small molecule therapies have been approved by the FDA to treat anaplastic large cell lymphoma? | There are no drug Small molecule therapies approved to treat anaplastic large cell lymphoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anaplastic large cell lymphoma" OR LOWER(mesh_heading) = "anaplastic large cell lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.661 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tinnitus? | There are no drug Small molecule therapies approved to treat Tinnitus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tinnitus" OR LOWER(mesh_heading) = "tinnitus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.236 | Q16 | What Protein therapies have been approved by the FDA to treat neuroendocrine neoplasm? | There are no drug Protein therapies approved to treat neuroendocrine neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroendocrine neoplasm" OR LOWER(mesh_heading) = "neuroendocrine neoplasm") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.738 | Q16 | What Small molecule therapies have been approved by the FDA to treat allergic conjunctivitis? | There are 10 Small molecule therapy drugs that are approved to treat allergic conjunctivitis which are as follows: Prednisone, Loteprednol Etabonate, Dexamethasone, Prednisolone Acetate, Bepotastine Besylate, Carbinoxamine Maleate, Alcaftadine, Azelastine Hydrochloride, Olopatadine Hydrochloride, and Levocetirizine Dihydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "allergic conjunctivitis" OR LOWER(mesh_heading) = "allergic conjunctivitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217651', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_217859', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_218067', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_218275', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_218483', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_218691', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_218899', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_219107', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_219315', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_219523', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_219731', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_219939', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_220147', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_220355', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_220563', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_220771', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225415', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225423', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225431', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225439', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225447', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225455', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225463', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225471', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225479', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225487', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225495', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225503', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225511', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225519', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225527', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225535', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225543', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225551', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225559', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225567', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225575', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225583', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225591', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225599', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_225607', 'drugName': 'Loteprednol Etabonate', 'tradeNames_list': "['Airex', 'Alrex', 'Eysuvis', 'Inveltys', 'Lotemax', 'Lotemax sm']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_226347', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_226632', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_226917', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_227202', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_227487', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_227772', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_228057', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_228342', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_228627', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_228912', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_229197', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_229482', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_229767', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_230052', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_230337', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_230622', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_230907', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_231192', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_231477', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_231762', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_232047', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_232332', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_243745', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_243762', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_243779', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_243796', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455769', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455772', 'drugName': 'Bepotastine Besylate', 'tradeNames_list': "['Bepreve']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455851', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455857', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455861', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455863', 'drugName': 'Alcaftadine', 'tradeNames_list': "['Lastacaft']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455869', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455877', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455885', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455893', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455901', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455909', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455917', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455925', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455933', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455941', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455949', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455955', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455959', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455963', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455967', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455971', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455975', 'drugName': 'Olopatadine Hydrochloride', 'tradeNames_list': "['Olopatadine hydrochloride', 'Pataday', 'Pataday once daily reliefPataday twice daily relief', 'Patanase', 'Patanol', 'Pazeo']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}, {'UUID': 'DrugTargetsIndication121923_text_455995', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_list': "['Levocetirizine dihydrochloride', 'Xusal', 'Xyzal', 'Xyzal allergy 24hrXyzall']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Conjunctivitis, Allergic', 'efo_term': 'allergic conjunctivitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1290 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant rhabdoid tumour? | There are no drug Small molecule therapies approved to treat malignant rhabdoid tumour. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant rhabdoid tumour" OR LOWER(mesh_heading) = "malignant rhabdoid tumour") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1437 | Q16 | What Small molecule therapies have been approved by the FDA to treat pancreatic ductal adenocarcinoma? | There are no drug Small molecule therapies approved to treat pancreatic ductal adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatic ductal adenocarcinoma" OR LOWER(mesh_heading) = "pancreatic ductal adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.942 | Q16 | What Small molecule therapies have been approved by the FDA to treat colorectal adenocarcinoma? | Regorafenib is the only Small molecule therapy approved by the FDA to treat colorectal adenocarcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal adenocarcinoma" OR LOWER(mesh_heading) = "colorectal adenocarcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_664064', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664100', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664136', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664172', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664208', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664244', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664280', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664316', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664352', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664388', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664424', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664460', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664496', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664532', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664568', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664604', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664640', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664676', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664712', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664748', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664784', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664820', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664856', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664892', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664928', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_664964', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665000', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665036', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665072', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665108', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665144', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665180', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665216', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665252', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665288', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665324', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665360', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665396', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665432', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665468', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665504', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665540', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665576', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665612', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665648', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665684', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665720', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665756', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665792', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665828', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665864', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665900', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665936', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_665972', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666008', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666044', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666080', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666116', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666152', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666188', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666224', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666260', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666296', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666332', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666368', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666404', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666440', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666476', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666512', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666548', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666584', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666620', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666656', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666692', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666728', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666764', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666800', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666836', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666872', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666908', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666944', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_666980', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667016', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667052', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667088', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667124', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667160', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667196', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667232', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_667268', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal adenocarcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1074 | Q16 | What Small molecule therapies have been approved by the FDA to treat fibrosarcoma? | There are no drug Small molecule therapies approved to treat fibrosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fibrosarcoma" OR LOWER(mesh_heading) = "fibrosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.109 | Q16 | What Protein therapies have been approved by the FDA to treat breast cancer? | Goserelin Acetate is the only Protein therapy approved by the FDA to treat breast cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breast cancer" OR LOWER(mesh_heading) = "breast cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1096829', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1096843', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1096857', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer'}, {'UUID': 'DrugTargetsIndication121923_text_1096871', 'drugName': 'Goserelin Acetate', 'tradeNames_list': "['Novgos', 'Zoladex', 'Zoladex la']", 'drugType': 'Protein', 'actionType': 'agonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1371 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuroblastoma? | There are no drug Small molecule therapies approved to treat neuroblastoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuroblastoma" OR LOWER(mesh_heading) = "neuroblastoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.572 | Q16 | What Small molecule therapies have been approved by the FDA to treat Ocular pain? | There are 2 Small molecule therapy drugs that are approved to treat Ocular pain which are as follows: Ketorolac Tromethamine and Bromfenac Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ocular pain" OR LOWER(mesh_heading) = "ocular pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_841766', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841782', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841798', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841814', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841830', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841846', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841862', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841878', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841894', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841910', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841926', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841942', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841958', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841974', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_841990', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842006', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842022', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842038', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842054', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842070', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842086', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842102', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842118', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842134', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842150', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842166', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842182', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842198', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842214', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842230', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842246', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842262', 'drugName': 'Ketorolac Tromethamine', 'tradeNames_list': "['Acular', 'Acular ls', 'Acular preservative free', 'AcuvailKetorolac tromethamine', 'Sprix', 'Toradol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842542', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842545', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842548', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842551', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842554', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842557', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842560', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842563', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842566', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842569', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842572', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842575', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842578', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842581', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842584', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842587', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842590', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842593', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842596', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842599', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842602', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842605', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842608', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}, {'UUID': 'DrugTargetsIndication121923_text_842611', 'drugName': 'Bromfenac Sodium', 'tradeNames_list': "['Bromday', 'Bromfenac sodium', 'Bromsite', 'Prolensa', 'Xibrom']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Pain', 'efo_term': 'Ocular pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.898 | Q16 | What Small molecule therapies have been approved by the FDA to treat childhood germ cell tumor? | There are no drug Small molecule therapies approved to treat childhood germ cell tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "childhood germ cell tumor" OR LOWER(mesh_heading) = "childhood germ cell tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.955 | Q16 | What Small molecule therapies have been approved by the FDA to treat congestive heart failure? | There are 10 Small molecule therapy drugs that are approved to treat congestive heart failure which are as follows: Carvedilol, Tolvaptan, Metoprolol Succinate, Nitroglycerin, Amlodipine Besylate, Lisinopril, Enalapril Maleate, Spironolactone, Ivabradine Hydrochloride, and Torsemide. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "congestive heart failure" OR LOWER(mesh_heading) = "congestive heart failure") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_356976', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357008', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357040', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357072', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357104', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357136', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357168', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357200', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357232', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357264', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357296', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357328', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357360', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357392', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357424', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357456', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357488', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357520', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357552', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357584', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357616', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357648', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357680', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357712', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357744', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357776', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357808', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357840', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357872', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357904', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357936', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_357968', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358000', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358032', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358064', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358096', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358128', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358160', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358192', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358224', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358256', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358288', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358320', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358352', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358384', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358416', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358448', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358480', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358512', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358544', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358576', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358608', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358640', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358672', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358704', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358736', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358768', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358800', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358832', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358864', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358896', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358928', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358960', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_358992', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359024', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359056', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359088', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359120', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359152', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359184', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359216', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359248', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359280', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359312', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359344', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359376', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359408', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359440', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359472', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359504', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000188778', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359536', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359568', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359600', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359632', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359664', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359696', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359728', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359760', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359792', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359824', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359856', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359888', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359920', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359952', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_359984', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_360016', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_360048', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_360080', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_360112', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}, {'UUID': 'DrugTargetsIndication121923_text_360144', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000171873', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Heart Failure', 'efo_term': 'congestive heart failure'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1057 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial Mediterranean fever? | Colchicine is the only Small molecule therapy approved by the FDA to treat familial Mediterranean fever. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial mediterranean fever" OR LOWER(mesh_heading) = "familial mediterranean fever") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_70058', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70096', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70134', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70172', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70210', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70248', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70286', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70324', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70362', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70400', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70438', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70476', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70514', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70552', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70590', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70628', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70666', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70704', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70742', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70780', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70818', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70856', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70894', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70932', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_70970', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71008', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71046', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71084', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71122', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71160', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71198', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71236', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71274', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71312', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71350', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71388', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71426', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71464', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71502', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71540', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71578', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71616', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71654', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71692', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71730', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71768', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71806', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71844', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71882', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71920', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71958', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_71996', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72034', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72072', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72110', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72148', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72186', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72224', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72262', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72300', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72338', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72376', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72414', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72452', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72490', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72528', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72566', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72604', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72642', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72680', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72718', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72756', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72794', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72832', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72870', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72908', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72946', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_72984', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73022', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73060', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73098', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73136', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73174', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73212', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73250', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73288', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73326', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73364', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73402', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73440', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73478', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73516', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73554', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73592', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73630', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73668', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73706', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73744', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73782', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}, {'UUID': 'DrugTargetsIndication121923_text_73820', 'drugName': 'Colchicine', 'tradeNames_list': "['Colchicine', 'Colcrys', 'Gloperba', 'Mitigare']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 1961, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Mediterranean Fever', 'efo_term': 'familial Mediterranean fever'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1185 | Q16 | What Small molecule therapies have been approved by the FDA to treat ileus? | There are no drug Small molecule therapies approved to treat ileus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ileus" OR LOWER(mesh_heading) = "ileus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1202 | Q16 | What Small molecule therapies have been approved by the FDA to treat intermediate coronary syndrome? | There are no drug Small molecule therapies approved to treat intermediate coronary syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intermediate coronary syndrome" OR LOWER(mesh_heading) = "intermediate coronary syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1269 | Q16 | What Small molecule therapies have been approved by the FDA to treat lymphoblastic lymphoma? | There are 2 Small molecule therapy drugs that are approved to treat lymphoblastic lymphoma which are as follows: Dasatinib and Methotrexate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoblastic lymphoma" OR LOWER(mesh_heading) = "lymphoblastic lymphoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_713212', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713290', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713368', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713446', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713524', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713602', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713680', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713758', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713836', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713914', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_713992', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714070', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714148', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714226', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714304', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714382', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714460', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714538', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714616', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714694', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714772', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714850', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_714928', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715006', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715084', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715162', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715240', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715318', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715396', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715474', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715552', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715630', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715708', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715786', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715864', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_715942', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716020', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716098', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716176', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716254', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716332', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716410', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716488', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716566', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716644', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716722', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716800', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716878', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_716956', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717034', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717112', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717190', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717268', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717346', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717424', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717502', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717580', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717658', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717736', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717814', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717892', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_717970', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718048', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718126', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718204', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718282', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718360', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718438', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718516', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718594', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718672', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718750', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186716', 'approvedSymbol': 'BCR', 'approvedName': 'BCR activator of RhoGEF and GTPase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718828', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718906', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_718984', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719062', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719140', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719218', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719296', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719374', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719452', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719530', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719608', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719686', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719764', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719842', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719920', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_719998', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720076', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720154', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720232', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720310', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720388', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720466', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720544', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720622', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101336', 'approvedSymbol': 'HCK', 'approvedName': 'HCK proto-oncogene, Src family tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720700', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720778', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720856', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}, {'UUID': 'DrugTargetsIndication121923_text_720934', 'drugName': 'Dasatinib', 'tradeNames_list': "['Dasatinib', 'Sprycel']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'lymphoblastic lymphoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.892 | Q16 | What Small molecule therapies have been approved by the FDA to treat cheilitis? | There are no drug Small molecule therapies approved to treat cheilitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cheilitis" OR LOWER(mesh_heading) = "cheilitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1477 | Q16 | What Small molecule therapies have been approved by the FDA to treat photosensitive epilepsy? | There are no drug Small molecule therapies approved to treat photosensitive epilepsy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "photosensitive epilepsy" OR LOWER(mesh_heading) = "photosensitive epilepsy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.858 | Q16 | What Small molecule therapies have been approved by the FDA to treat bursitis? | There are 3 Small molecule therapy drugs that are approved to treat bursitis which are as follows: Triamcinolone Acetonide, Dexamethasone, and Naproxen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bursitis" OR LOWER(mesh_heading) = "bursitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217668', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_217876', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218084', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218292', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218500', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218708', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_218916', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219124', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219332', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219540', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219748', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_219956', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220164', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220372', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220580', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_220788', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_221881', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_221889', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_221946', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_221954', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222011', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222019', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222076', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222084', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222141', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222149', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222206', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222214', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222271', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222279', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_222336', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_222344', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_226365', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226376', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_226650', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226661', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_226935', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_226946', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_227220', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227231', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_227505', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227516', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_227790', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_227801', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_228075', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228086', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_228360', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_228645', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_228930', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_228941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_229215', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_229500', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229511', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_229785', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_229796', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_230070', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230081', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_230355', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230366', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_230640', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230651', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_230925', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_230936', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_231210', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231221', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_231495', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231506', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_231780', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_231791', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_232065', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_232076', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_232350', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_232361', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'bursitis'}, {'UUID': 'DrugTargetsIndication121923_text_637794', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_637909', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638024', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638139', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638254', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638369', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638484', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638599', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638714', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638829', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_638944', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639059', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639174', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639289', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639404', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639519', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639634', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639749', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639864', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_639979', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640094', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640209', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640324', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}, {'UUID': 'DrugTargetsIndication121923_text_640439', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bursitis', 'efo_term': 'frozen shoulder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.740 | Q16 | What Small molecule therapies have been approved by the FDA to treat allergic disease? | There are 3 Small molecule therapy drugs that are approved to treat allergic disease which are as follows: Epinephrine, Phenylephrine Hydrochloride, and Fexofenadine Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "allergic disease" OR LOWER(mesh_heading) = "allergic disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360837', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_360890', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_360943', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_360996', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361049', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361102', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361155', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361208', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361261', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361314', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361367', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361420', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361473', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361526', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361579', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361632', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361685', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361738', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361791', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361844', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361897', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_361950', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362003', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362056', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362109', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362162', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362215', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362268', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362321', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362374', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362427', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362480', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362533', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362586', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362639', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362692', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362745', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362798', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362851', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362904', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_362957', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363010', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363063', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363116', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363169', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363222', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363275', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363328', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363381', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363434', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363487', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363540', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363593', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363646', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363699', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363752', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363805', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363858', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363911', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_363964', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364017', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364070', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364123', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364176', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364229', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364282', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364335', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364388', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364441', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364494', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364547', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364600', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364653', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364706', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364759', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364812', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364865', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364918', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_364971', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365024', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365077', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365130', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365183', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365236', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365289', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365342', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365395', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365448', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365501', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365554', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365607', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365660', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365713', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365766', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365819', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365872', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365925', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_365978', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_366031', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}, {'UUID': 'DrugTargetsIndication121923_text_366084', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypersensitivity', 'efo_term': 'allergic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.723 | Q16 | What Small molecule therapies have been approved by the FDA to treat adult acute respiratory distress syndrome? | There are no drug Small molecule therapies approved to treat adult acute respiratory distress syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "adult acute respiratory distress syndrome" OR LOWER(mesh_heading) = "adult acute respiratory distress syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.458 | Q16 | What Small molecule therapies have been approved by the FDA to treat Glycogen storage disease due to glucose-6-phosphatase deficiency? | There are no drug Small molecule therapies approved to treat Glycogen storage disease due to glucose-6-phosphatase deficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "glycogen storage disease due to glucose-6-phosphatase deficiency" OR LOWER(mesh_heading) = "glycogen storage disease due to glucose-6-phosphatase deficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.266 | Q16 | What Protein therapies have been approved by the FDA to treat pouchitis? | There are no drug Protein therapies approved to treat pouchitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pouchitis" OR LOWER(mesh_heading) = "pouchitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.76 | Q16 | What Protein therapies have been approved by the FDA to treat acne? | There are no drug Protein therapies approved to treat acne. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acne" OR LOWER(mesh_heading) = "acne") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.448 | Q16 | What Small molecule therapies have been approved by the FDA to treat Gaucher disease? | Eliglustat Tartrate is the only Small molecule therapy approved by the FDA to treat Gaucher disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gaucher disease" OR LOWER(mesh_heading) = "gaucher disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097554', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097555', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097556', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097557', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097558', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097559', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097560', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097561', 'drugName': 'Eliglustat Tartrate', 'tradeNames_list': "['Cerdelga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148154', 'approvedSymbol': 'UGCG', 'approvedName': 'UDP-glucose ceramide glucosyltransferase', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gaucher Disease', 'efo_term': 'Gaucher disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.398 | Q16 | What Small molecule therapies have been approved by the FDA to treat Constipation? | There are 5 Small molecule therapy drugs that are approved to treat Constipation which are as follows: Naldemedine Tosylate, Methylnaltrexone Bromide, Alvimopan, Naloxone, and Lubiprostone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "constipation" OR LOWER(mesh_heading) = "constipation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_763351', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763353', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763355', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763357', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763359', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763361', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763363', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763365', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763367', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763369', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763371', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763373', 'drugName': 'Naloxegol Oxalate', 'tradeNames_list': "['Movantik']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763374', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_763376', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763377', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_763379', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763380', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_763382', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_763383', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_763385', 'drugName': 'Naldemedine Tosylate', 'tradeNames_list': "['Symproic']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766642', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766645', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766648', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766651', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766654', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766657', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766660', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766663', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766666', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766669', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766672', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766675', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766678', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766681', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766684', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766687', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766690', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766693', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766696', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766699', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766702', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766705', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766708', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766711', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766714', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766717', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766720', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766723', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766726', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766729', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766732', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766735', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766738', 'drugName': 'Methylnaltrexone Bromide', 'tradeNames_list': "['Relistor']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_766793', 'drugName': 'Alvimopan', 'tradeNames_list': "['Entereg']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791375', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791402', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791429', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791456', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791483', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791510', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791537', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791564', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791591', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791618', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791645', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791672', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791699', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791726', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791753', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791780', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791807', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791834', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791861', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791888', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791915', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791942', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791969', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_791996', 'drugName': 'Naloxone', 'tradeNames_list': "['Nalone', 'Narcan', 'Narcanti']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000116329', 'approvedSymbol': 'OPRD1', 'approvedName': 'opioid receptor delta 1', 'yearOfFirstApproval': 1971, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1094305', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094309', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094313', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1094317', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_list': "['Ibsrela']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066230', 'approvedSymbol': 'SLC9A3', 'approvedName': 'solute carrier family 9 member A3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193384', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193387', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193389', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193392', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193394', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193397', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193399', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193402', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193404', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193407', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193409', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193412', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193414', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193417', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193419', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193422', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}, {'UUID': 'DrugTargetsIndication121923_text_1193424', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'Constipation'}, {'UUID': 'DrugTargetsIndication121923_text_1193427', 'drugName': 'Lubiprostone', 'tradeNames_list': "['Amitiza']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000114859', 'approvedSymbol': 'CLCN2', 'approvedName': 'chloride voltage-gated channel 2', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Constipation', 'efo_term': 'constipation disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.177 | Q16 | What Protein therapies have been approved by the FDA to treat hypertension? | There are no drug Protein therapies approved to treat hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypertension" OR LOWER(mesh_heading) = "hypertension") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1051 | Q16 | What Small molecule therapies have been approved by the FDA to treat eye disease? | There are 3 Small molecule therapy drugs that are approved to treat eye disease which are as follows: Dexamethasone, Lifitegrast, and Sirolimus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eye disease" OR LOWER(mesh_heading) = "eye disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226338', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_226623', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_226908', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_227193', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_227478', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_227763', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_228048', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_228333', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_228618', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_228903', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_229188', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_229473', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_229758', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_230043', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_230328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_230613', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_230898', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_231183', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_231468', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_231753', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_232038', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_232323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053355', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053359', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053363', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053367', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053371', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053375', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053379', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053383', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053387', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053391', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053395', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053399', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053403', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053407', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053411', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053415', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000005844', 'approvedSymbol': 'ITGAL', 'approvedName': 'integrin subunit alpha L', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053419', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053423', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053427', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053431', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053435', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053439', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053443', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053447', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053451', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053455', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053459', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053463', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053467', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053471', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053475', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1053479', 'drugName': 'Lifitegrast', 'tradeNames_list': "['Xiidra']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160255', 'approvedSymbol': 'ITGB2', 'approvedName': 'integrin subunit beta 2', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084429', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084564', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084699', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}, {'UUID': 'DrugTargetsIndication121923_text_1084834', 'drugName': 'Sirolimus', 'tradeNames_list': "['Fyarro', 'Hyftor', 'Rapamune', 'Sirolimus']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1531 | Q16 | What Small molecule therapies have been approved by the FDA to treat primitive neuroectodermal tumor? | There are no drug Small molecule therapies approved to treat primitive neuroectodermal tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primitive neuroectodermal tumor" OR LOWER(mesh_heading) = "primitive neuroectodermal tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1314 | Q16 | What Small molecule therapies have been approved by the FDA to treat metabolic syndrome? | There are no drug Small molecule therapies approved to treat metabolic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "metabolic syndrome" OR LOWER(mesh_heading) = "metabolic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1210 | Q16 | What Small molecule therapies have been approved by the FDA to treat intestinal obstruction? | There are no drug Small molecule therapies approved to treat intestinal obstruction. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intestinal obstruction" OR LOWER(mesh_heading) = "intestinal obstruction") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.599 | Q16 | What Small molecule therapies have been approved by the FDA to treat Premature ovarian insufficiency? | Estradiol is the only Small molecule therapy approved by the FDA to treat Premature ovarian insufficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "premature ovarian insufficiency" OR LOWER(mesh_heading) = "premature ovarian insufficiency") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_823978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_824978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_825978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_826978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827078', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827128', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827178', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827228', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827278', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827328', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827378', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827428', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827478', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827528', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827578', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827628', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827678', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827728', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827778', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827828', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827878', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827928', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_827978', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}, {'UUID': 'DrugTargetsIndication121923_text_828028', 'drugName': 'Estradiol', 'tradeNames_list': "['Adgyn estro', 'Alora', 'Aquagen', 'Bedol', 'Climara', 'Climara ProDermestril 100', 'Dermestril 25', 'Dermestril 50', 'Dermestril septem 25Dermestril septem 50', 'Dermestril septem 75', 'Divigel', 'E-CypionateElestrim', 'Elestrin', 'Elleste solo', 'Elleste solo mx 40Elleste solo mx 80', 'Esclim', 'Estrace', 'Estraderm', 'Estraderm mx 100Estraderm mx 25', 'Estraderm mx 50', 'Estraderm mx 75', 'Estraderm tts 100Estraderm tts 25', 'Estraderm tts 50', 'Estradiol', 'Estrasorb', 'EstringEstrogel', 'Evamist', 'Evorel 100', 'Evorel 25', 'Evorel 50', 'Evorel 75Fematrix 40', 'Fematrix 80', 'Fempatch', 'Femseven 100', 'Femseven 50Femseven 75', 'Gvnodiol', 'Gynodiol', 'Gynogen', 'Imvexxy', 'InnofemMenorest 37.5', 'Menorest 50', 'Menorest 75', 'Menoring 50', 'MenostarMinivelle', 'Oestradiol', 'Progynova ts', 'Sandrena', 'Vagifem', 'Vagifem 18Vagifem 8', 'Vivelle', 'Vivelle-dot', 'Zumenon']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 1975, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Ovarian Insufficiency', 'efo_term': 'Premature ovarian insufficiency'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.62 | Q16 | What Protein therapies have been approved by the FDA to treat Respiratory Syncytial Virus Infection? | There are no drug Protein therapies approved to treat Respiratory Syncytial Virus Infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory syncytial virus infection" OR LOWER(mesh_heading) = "respiratory syncytial virus infection") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.880 | Q16 | What Small molecule therapies have been approved by the FDA to treat cerebral arterial disease? | There are no drug Small molecule therapies approved to treat cerebral arterial disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cerebral arterial disease" OR LOWER(mesh_heading) = "cerebral arterial disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1308 | Q16 | What Small molecule therapies have been approved by the FDA to treat menopause? | There are 2 Small molecule therapy drugs that are approved to treat menopause which are as follows: Ospemifene and Estradiol Acetate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "menopause" OR LOWER(mesh_heading) = "menopause") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_823727', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823731', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823735', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823739', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823743', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823747', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823751', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823755', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823759', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823763', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823767', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823771', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823775', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823779', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823783', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823787', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823791', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823795', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823799', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823803', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823807', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823811', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823815', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823819', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823823', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823827', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823831', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823835', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823839', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823843', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823847', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823851', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823855', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823859', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823863', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823867', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823871', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823875', 'drugName': 'Ospemifene', 'tradeNames_list': "['Osphena', 'Senshio']", 'drugType': 'Small molecule', 'actionType': 'modulator', 'target': 'ENSG00000140009', 'approvedSymbol': 'ESR2', 'approvedName': 'estrogen receptor 2', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823877', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823879', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}, {'UUID': 'DrugTargetsIndication121923_text_823881', 'drugName': 'Estradiol Acetate', 'tradeNames_list': "['Femring', 'Femtrace']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000091831', 'approvedSymbol': 'ESR1', 'approvedName': 'estrogen receptor 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Menopause', 'efo_term': 'menopause'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1755 | Q16 | What Small molecule therapies have been approved by the FDA to treat viral pneumonia? | There are no drug Small molecule therapies approved to treat viral pneumonia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "viral pneumonia" OR LOWER(mesh_heading) = "viral pneumonia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.280 | Q16 | What Protein therapies have been approved by the FDA to treat pure red-cell aplasia? | There are no drug Protein therapies approved to treat pure red-cell aplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pure red-cell aplasia" OR LOWER(mesh_heading) = "pure red-cell aplasia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.37 | Q16 | What Protein therapies have been approved by the FDA to treat Diarrhea? | There are no drug Protein therapies approved to treat Diarrhea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diarrhea" OR LOWER(mesh_heading) = "diarrhea") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.666 | Q16 | What Small molecule therapies have been approved by the FDA to treat Tularemia? | Doxycycline is the only Small molecule therapy approved by the FDA to treat Tularemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tularemia" OR LOWER(mesh_heading) = "tularemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1037853', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1037928', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038003', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038078', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038153', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038228', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038303', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038378', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038453', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038528', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038603', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038678', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038753', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038828', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038903', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1038978', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039053', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039128', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039203', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039278', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039353', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039428', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039503', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039578', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039653', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039728', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039803', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039878', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1039953', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040028', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040103', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040178', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040253', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040328', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040403', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040478', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040553', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040628', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040703', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040778', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040853', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1040928', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1041003', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}, {'UUID': 'DrugTargetsIndication121923_text_1041078', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000118113', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tularemia', 'efo_term': 'Tularemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1589 | Q16 | What Small molecule therapies have been approved by the FDA to treat rhinitis? | There are no drug Small molecule therapies approved to treat rhinitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rhinitis" OR LOWER(mesh_heading) = "rhinitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1547 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary edema? | There are no drug Small molecule therapies approved to treat pulmonary edema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary edema" OR LOWER(mesh_heading) = "pulmonary edema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.985 | Q16 | What Small molecule therapies have been approved by the FDA to treat developmental disability? | There are no drug Small molecule therapies approved to treat developmental disability. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "developmental disability" OR LOWER(mesh_heading) = "developmental disability") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1386 | Q16 | What Small molecule therapies have been approved by the FDA to treat nicotine dependence? | Nicotine Polacrilex is the only Small molecule therapy approved by the FDA to treat nicotine dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nicotine dependence" OR LOWER(mesh_heading) = "nicotine dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857237', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857239', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857241', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857243', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857245', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857247', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160716', 'approvedSymbol': 'CHRNB2', 'approvedName': 'cholinergic receptor nicotinic beta 2 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857249', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857251', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857253', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857255', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857257', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}, {'UUID': 'DrugTargetsIndication121923_text_857259', 'drugName': 'Nicotine Polacrilex', 'tradeNames_list': "['Commit', 'Nicorette', 'Nicorette (mint)', 'Nicotine polacrilex', 'Thrive']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000101204', 'approvedSymbol': 'CHRNA4', 'approvedName': 'cholinergic receptor nicotinic alpha 4 subunit', 'yearOfFirstApproval': 1984, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tobacco Use Disorder', 'efo_term': 'nicotine dependence'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.744 | Q16 | What Small molecule therapies have been approved by the FDA to treat altitude sickness? | There are no drug Small molecule therapies approved to treat altitude sickness. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "altitude sickness" OR LOWER(mesh_heading) = "altitude sickness") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.192 | Q16 | What Protein therapies have been approved by the FDA to treat islet cell tumor? | There are no drug Protein therapies approved to treat islet cell tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "islet cell tumor" OR LOWER(mesh_heading) = "islet cell tumor") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.927 | Q16 | What Small molecule therapies have been approved by the FDA to treat circadian rhythm sleep disorder? | There are no drug Small molecule therapies approved to treat circadian rhythm sleep disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "circadian rhythm sleep disorder" OR LOWER(mesh_heading) = "circadian rhythm sleep disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.460 | Q16 | What Small molecule therapies have been approved by the FDA to treat Granulomatosis with Polyangiitis? | Avacopan is the only Small molecule therapy approved by the FDA to treat Granulomatosis with Polyangiitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "granulomatosis with polyangiitis" OR LOWER(mesh_heading) = "granulomatosis with polyangiitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191849', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Granulomatosis with Polyangiitis', 'efo_term': 'Granulomatosis with Polyangiitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191857', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Granulomatosis with Polyangiitis', 'efo_term': 'Granulomatosis with Polyangiitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.680 | Q16 | What Small molecule therapies have been approved by the FDA to treat Vulvar Lichen Sclerosus? | There are no drug Small molecule therapies approved to treat Vulvar Lichen Sclerosus. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vulvar lichen sclerosus" OR LOWER(mesh_heading) = "vulvar lichen sclerosus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.768 | Q16 | What Small molecule therapies have been approved by the FDA to treat ankle fracture? | There are no drug Small molecule therapies approved to treat ankle fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ankle fracture" OR LOWER(mesh_heading) = "ankle fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1590 | Q16 | What Small molecule therapies have been approved by the FDA to treat rhinoscleroma? | There are no drug Small molecule therapies approved to treat rhinoscleroma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "rhinoscleroma" OR LOWER(mesh_heading) = "rhinoscleroma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.734 | Q16 | What Small molecule therapies have been approved by the FDA to treat alcoholic liver cirrhosis? | There are no drug Small molecule therapies approved to treat alcoholic liver cirrhosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alcoholic liver cirrhosis" OR LOWER(mesh_heading) = "alcoholic liver cirrhosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.415 | Q16 | What Small molecule therapies have been approved by the FDA to treat Drooling? | There are no drug Small molecule therapies approved to treat Drooling. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "drooling" OR LOWER(mesh_heading) = "drooling") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1107 | Q16 | What Small molecule therapies have been approved by the FDA to treat gestational trophoblastic neoplasm? | There are no drug Small molecule therapies approved to treat gestational trophoblastic neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gestational trophoblastic neoplasm" OR LOWER(mesh_heading) = "gestational trophoblastic neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.833 | Q16 | What Small molecule therapies have been approved by the FDA to treat bone neoplasm? | There are no drug Small molecule therapies approved to treat bone neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bone neoplasm" OR LOWER(mesh_heading) = "bone neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.620 | Q16 | What Small molecule therapies have been approved by the FDA to treat Sepsis? | There are no drug Small molecule therapies approved to treat Sepsis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sepsis" OR LOWER(mesh_heading) = "sepsis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.115 | Q16 | What Protein therapies have been approved by the FDA to treat cancer? | Carfilzomib is the only Protein therapy approved by the FDA to treat cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cancer" OR LOWER(mesh_heading) = "cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_267901', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_267928', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_267955', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_267982', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268009', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268036', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268063', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268090', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268117', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268144', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268171', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268198', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268225', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268252', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268279', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268306', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268333', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268360', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268387', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268414', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268441', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268468', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268495', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268522', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268549', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268576', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268603', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268630', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268657', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268684', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268711', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268738', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268765', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268792', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268819', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268846', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268873', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268900', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268927', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268954', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_268981', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269008', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269035', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269062', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269089', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269116', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269143', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269170', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269197', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269224', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269251', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269278', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269305', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269332', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269359', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269386', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269413', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000173692', 'approvedSymbol': 'PSMD1', 'approvedName': 'proteasome 26S subunit, non-ATPase 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269440', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269467', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269494', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269521', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269548', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269575', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269602', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269629', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269656', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269683', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269710', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269737', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269764', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269791', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269818', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269845', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269872', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269899', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269926', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269953', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_269980', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270007', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270034', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270061', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270088', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270115', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270142', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270169', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270196', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270223', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270250', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270277', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270304', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270331', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270358', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270385', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270412', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270439', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270466', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270493', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270520', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270547', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}, {'UUID': 'DrugTargetsIndication121923_text_270574', 'drugName': 'Carfilzomib', 'tradeNames_list': "['Kyprolis']", 'drugType': 'Protein', 'actionType': 'inhibitor', 'target': 'ENSG00000126067', 'approvedSymbol': 'PSMB2', 'approvedName': 'proteasome 20S subunit beta 2', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.421 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dyspnea? | There are no drug Small molecule therapies approved to treat Dyspnea. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dyspnea" OR LOWER(mesh_heading) = "dyspnea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1678 | Q16 | What Small molecule therapies have been approved by the FDA to treat systemic mastocytosis? | Midostaurin is the only Small molecule therapy approved by the FDA to treat systemic mastocytosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "systemic mastocytosis" OR LOWER(mesh_heading) = "systemic mastocytosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_667283', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667294', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667305', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667316', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667327', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667338', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000122025', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667349', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667360', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667371', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667382', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667393', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667404', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667415', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667426', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667437', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667448', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667459', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667470', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171132', 'approvedSymbol': 'PRKCE', 'approvedName': 'protein kinase C epsilon', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667481', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667492', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667503', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000166501', 'approvedSymbol': 'PRKCB', 'approvedName': 'protein kinase C beta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667514', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667525', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667536', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000115825', 'approvedSymbol': 'PRKD3', 'approvedName': 'protein kinase D3', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667547', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667558', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667569', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163558', 'approvedSymbol': 'PRKCI', 'approvedName': 'protein kinase C iota', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667580', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667591', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667602', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000154229', 'approvedSymbol': 'PRKCA', 'approvedName': 'protein kinase C alpha', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667613', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667624', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667635', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126583', 'approvedSymbol': 'PRKCG', 'approvedName': 'protein kinase C gamma', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667646', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667657', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667668', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000163932', 'approvedSymbol': 'PRKCD', 'approvedName': 'protein kinase C delta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667679', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667690', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667701', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000067606', 'approvedSymbol': 'PRKCZ', 'approvedName': 'protein kinase C zeta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667712', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667723', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667734', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000027075', 'approvedSymbol': 'PRKCH', 'approvedName': 'protein kinase C eta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667745', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667756', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667767', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000184304', 'approvedSymbol': 'PRKD1', 'approvedName': 'protein kinase D1', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667778', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667789', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}, {'UUID': 'DrugTargetsIndication121923_text_667800', 'drugName': 'Midostaurin', 'tradeNames_list': "['Rydapt']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065675', 'approvedSymbol': 'PRKCQ', 'approvedName': 'protein kinase C theta', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mastocytosis, Systemic', 'efo_term': 'systemic mastocytosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.977 | Q16 | What Small molecule therapies have been approved by the FDA to treat delirium? | There are no drug Small molecule therapies approved to treat delirium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "delirium" OR LOWER(mesh_heading) = "delirium") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.608 | Q16 | What Small molecule therapies have been approved by the FDA to treat Raynaud disease? | There are no drug Small molecule therapies approved to treat Raynaud disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "raynaud disease" OR LOWER(mesh_heading) = "raynaud disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1685 | Q16 | What Small molecule therapies have been approved by the FDA to treat tenosynovitis? | There are 3 Small molecule therapy drugs that are approved to treat tenosynovitis which are as follows: Prednisone, Triamcinolone Acetonide, and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tenosynovitis" OR LOWER(mesh_heading) = "tenosynovitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_217883', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218091', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218299', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218507', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218715', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_218923', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219131', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219339', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219547', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219755', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_219963', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220171', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220379', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220587', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_220795', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_221883', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_221948', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222013', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222078', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222143', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222208', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222273', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_222338', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226372', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226657', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_226942', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227227', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227512', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_227797', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228082', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228367', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228652', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_228937', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229222', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229507', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_229792', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230077', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230362', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230647', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_230932', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231217', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231502', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_231787', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_232072', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}, {'UUID': 'DrugTargetsIndication121923_text_232357', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tenosynovitis', 'efo_term': 'tenosynovitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.90 | Q16 | What Protein therapies have been approved by the FDA to treat amyloidosis? | There are no drug Protein therapies approved to treat amyloidosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "amyloidosis" OR LOWER(mesh_heading) = "amyloidosis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.856 | Q16 | What Small molecule therapies have been approved by the FDA to treat bullous pemphigoid? | There are no drug Small molecule therapies approved to treat bullous pemphigoid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bullous pemphigoid" OR LOWER(mesh_heading) = "bullous pemphigoid") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1339 | Q16 | What Small molecule therapies have been approved by the FDA to treat multiple bone fractures? | There are no drug Small molecule therapies approved to treat multiple bone fractures. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "multiple bone fractures" OR LOWER(mesh_heading) = "multiple bone fractures") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1684 | Q16 | What Small molecule therapies have been approved by the FDA to treat tendinitis? | Naproxen is the only Small molecule therapy approved by the FDA to treat tendinitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tendinitis" OR LOWER(mesh_heading) = "tendinitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838347', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838388', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838429', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838470', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838511', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838552', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838593', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838634', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838675', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838716', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838757', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838798', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838839', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838880', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838921', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_838962', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839003', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839044', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839085', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839126', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839167', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839208', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839249', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839290', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839331', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839372', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839413', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839454', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839495', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839536', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839577', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839618', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839659', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}, {'UUID': 'DrugTargetsIndication121923_text_839700', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tendinopathy', 'efo_term': 'tendinitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.760 | Q16 | What Small molecule therapies have been approved by the FDA to treat anemia? | There are 4 Small molecule therapy drugs that are approved to treat anemia which are as follows: Triamcinolone Acetonide, Prednisolone Acetate, Lenalidomide, and Azacitidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anemia" OR LOWER(mesh_heading) = "anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_221887', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_221952', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222017', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222082', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222147', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222212', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222277', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_222342', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_243747', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_243764', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_243781', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_243798', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1105737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1105824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1105911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1105913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1105998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106435', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106522', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106609', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106696', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106783', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106870', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1106955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1106957', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107044', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107131', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107218', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107305', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107392', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107479', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107566', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107653', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107740', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107827', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1107914', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1107999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108001', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108088', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108175', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108262', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108349', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108436', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108523', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108610', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108697', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108784', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108871', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1108956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1108958', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109045', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109132', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109219', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109306', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109393', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1109478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)'}, {'UUID': 'DrugTargetsIndication121923_text_1109480', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113851', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon', 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.502 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hyperphenylalaninemia? | Sapropterin Dihydrochloride is the only Small molecule therapy approved by the FDA to treat Hyperphenylalaninemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hyperphenylalaninemia" OR LOWER(mesh_heading) = "hyperphenylalaninemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192262', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192273', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192284', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192295', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192306', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192317', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192328', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192339', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192350', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192361', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192372', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192383', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192394', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192405', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192416', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192427', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192438', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192449', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192460', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192471', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192482', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192493', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192504', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192515', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192526', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192537', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192548', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192559', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192570', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192581', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192592', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192603', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192614', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192625', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192636', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192647', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}, {'UUID': 'DrugTargetsIndication121923_text_1192658', 'drugName': 'Sapropterin Dihydrochloride', 'tradeNames_list': "['Kuvan']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000171759', 'approvedSymbol': 'PAH', 'approvedName': 'phenylalanine hydroxylase', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Phenylketonurias', 'efo_term': 'Hyperphenylalaninemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.12 | Q16 | What Oligonucleotide therapies have been approved by the FDA to treat polyneuropathy? | There are 3 Oligonucleotide therapy drugs that are approved to treat polyneuropathy which are as follows: Inotersen Sodium, Vutrisiran, and Patisiran Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "polyneuropathy" OR LOWER(mesh_heading) = "polyneuropathy") AND LOWER(drugType) = "oligonucleotide" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097643', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097646', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097649', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097652', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097655', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097658', 'drugName': 'Inotersen Sodium', 'tradeNames_list': "['Tegsedi']", 'drugType': 'Oligonucleotide', 'actionType': 'antisense inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097661', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097663', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097665', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097667', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097669', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097671', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097673', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097675', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097677', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097679', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097681', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097683', 'drugName': 'Vutrisiran', 'tradeNames_list': "['Amvuttra']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097685', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097688', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097691', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097694', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097697', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097700', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097703', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097706', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097709', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097712', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097715', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097718', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097721', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097724', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097727', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}, {'UUID': 'DrugTargetsIndication121923_text_1097730', 'drugName': 'Patisiran Sodium', 'tradeNames_list': "['Onpattro']", 'drugType': 'Oligonucleotide', 'actionType': 'rnai inhibitor', 'target': 'ENSG00000118271', 'approvedSymbol': 'TTR', 'approvedName': 'transthyretin', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Polyneuropathies', 'efo_term': 'polyneuropathy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.399 | Q16 | What Small molecule therapies have been approved by the FDA to treat Corneal scarring? | Prednisolone Acetate is the only Small molecule therapy approved by the FDA to treat Corneal scarring. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "corneal scarring" OR LOWER(mesh_heading) = "corneal scarring") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243741', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Corneal Injuries', 'efo_term': 'Corneal scarring'}, {'UUID': 'DrugTargetsIndication121923_text_243758', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Corneal Injuries', 'efo_term': 'Corneal scarring'}, {'UUID': 'DrugTargetsIndication121923_text_243775', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Corneal Injuries', 'efo_term': 'Corneal scarring'}, {'UUID': 'DrugTargetsIndication121923_text_243792', 'drugName': 'Prednisolone Acetate', 'tradeNames_list': "['Econopred', 'Flo-pred', 'Meticortelone', 'Omnipred', 'Pred forte', 'Pred ftePred mild', 'Prednisolone acetate', 'Sterane', 'Ultracortenol']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Corneal Injuries', 'efo_term': 'Corneal scarring'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.286 | Q16 | What Protein therapies have been approved by the FDA to treat salivary gland carcinoma? | There are no drug Protein therapies approved to treat salivary gland carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "salivary gland carcinoma" OR LOWER(mesh_heading) = "salivary gland carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1075 | Q16 | What Small molecule therapies have been approved by the FDA to treat fibrosis? | Ribavirin is the only Small molecule therapy approved by the FDA to treat fibrosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fibrosis" OR LOWER(mesh_heading) = "fibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_937565', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_937567', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_937590', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_937592', 'drugName': 'Ribavirin', 'tradeNames_list': "['Copegus', 'Rebetol', 'Ribapak', 'Ribasphere', 'Ribavarin', 'RibavirinRibofluranosyl Carboxamide', 'Tribavirin', 'Viramid', 'Virazid', 'Virazole']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106348', 'approvedSymbol': 'IMPDH1', 'approvedName': 'inosine monophosphate dehydrogenase 1', 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'fibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_1094353', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094391', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094429', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094467', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094505', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094543', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094581', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094619', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}, {'UUID': 'DrugTargetsIndication121923_text_1094657', 'drugName': 'Spironolactone', 'tradeNames_list': "['Abbolactone', 'Aldactone', 'Carospir', 'Diatensec', 'Gx spironolLaractone', 'Spiretic', 'Spiroctan 100', 'Spiroctan 25', 'Spiroctan 50Spironolactone', 'Spirospare 100', 'Spirospare 25']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fibrosis', 'efo_term': 'cirrhosis of liver'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1200 | Q16 | What Small molecule therapies have been approved by the FDA to treat insulin resistance? | There are no drug Small molecule therapies approved to treat insulin resistance. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "insulin resistance" OR LOWER(mesh_heading) = "insulin resistance") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.695 | Q16 | What Small molecule therapies have been approved by the FDA to treat acromegaly? | Bromocriptine Mesylate is the only Small molecule therapy approved by the FDA to treat acromegaly. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acromegaly" OR LOWER(mesh_heading) = "acromegaly") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_201341', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201348', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201355', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201362', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201369', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201376', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201383', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201390', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201397', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201404', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201411', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201418', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201425', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201432', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201439', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201446', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201453', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201460', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201467', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201474', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201481', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201488', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201495', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201502', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201509', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201516', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201523', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201530', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201537', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201544', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201551', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201558', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201565', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201572', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201579', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201586', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201593', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201600', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201607', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201614', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201621', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201628', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201635', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201642', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201649', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201656', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201663', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201670', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201677', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201684', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201691', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201698', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201705', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201712', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201719', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201726', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201733', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201740', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201747', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201754', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201761', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201768', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201775', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201782', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201789', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201796', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201803', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201810', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201817', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201824', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201831', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201838', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201845', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201852', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201859', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201866', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201873', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201880', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201887', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201894', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201901', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201908', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201915', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201922', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201929', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201936', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201943', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201950', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201957', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201964', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201971', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201978', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201985', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201992', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_201999', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_202006', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_202013', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_202020', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_202027', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}, {'UUID': 'DrugTargetsIndication121923_text_202034', 'drugName': 'Bromocriptine Mesylate', 'tradeNames_list': "['Bromocriptine mesylate', 'Cycloset', 'Parlodel']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000149295', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2', 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acromegaly', 'efo_term': 'acromegaly'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1440 | Q16 | What Small molecule therapies have been approved by the FDA to treat pancreatic neoplasm? | There are no drug Small molecule therapies approved to treat pancreatic neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatic neoplasm" OR LOWER(mesh_heading) = "pancreatic neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1650 | Q16 | What Small molecule therapies have been approved by the FDA to treat spondylitis? | There are 3 Small molecule therapy drugs that are approved to treat spondylitis which are as follows: Indomethacin, Celecoxib, and Naproxen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "spondylitis" OR LOWER(mesh_heading) = "spondylitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828207', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828241', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828275', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828309', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828343', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828377', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828411', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828445', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828479', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828513', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828547', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828581', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_832948', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833059', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833170', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833281', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833392', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833503', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838346', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838387', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838428', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838469', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838510', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838551', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838592', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838633', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838674', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838715', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838756', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838797', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838838', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838879', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838920', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838961', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839002', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839043', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839084', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839125', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839166', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839207', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839248', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839289', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839330', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839371', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839412', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839453', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839494', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839535', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839576', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839617', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839658', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839699', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis', 'efo_term': 'spondylitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.694 | Q16 | What Small molecule therapies have been approved by the FDA to treat acne? | There are 10 Small molecule therapy drugs that are approved to treat acne which are as follows: Dexamethasone, Clascoterone, Drospirenone, Doxycycline Hyclate, Doxycycline, Tretinoin, Isotretinoin, Tazarotene, Adapalene, and Trifarotene. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acne" OR LOWER(mesh_heading) = "acne") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_226620', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_226905', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_227190', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_227475', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_227760', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_228045', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_228330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_228615', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_228900', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_229185', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_229470', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_229755', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_230040', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_230325', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_230610', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_230895', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_231180', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_231465', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_231750', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_232035', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_232320', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924370', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924372', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924374', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924376', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924378', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924380', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924382', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_924384', 'drugName': 'Clascoterone', 'tradeNames_list': "['Breezula', 'Winlevi']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169083', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor', 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939846', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939854', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939862', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939870', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939878', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939886', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939894', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939902', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939910', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939918', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939926', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082175', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939934', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939942', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939950', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939958', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939966', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939974', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939982', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939990', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_939998', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_940006', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_940014', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000151623', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2', 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036824', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036835', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036846', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036857', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036868', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036879', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036890', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036901', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036912', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036923', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036934', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036945', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036956', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036967', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036978', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1036989', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037000', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037011', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037022', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037033', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037044', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037055', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137673', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037066', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037077', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037088', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037099', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037110', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037121', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037132', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037143', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037154', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037165', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037176', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037187', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037198', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037209', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037220', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037231', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037242', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037253', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037264', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037275', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037286', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037297', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196611', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037308', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037319', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037330', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}, {'UUID': 'DrugTargetsIndication121923_text_1037341', 'drugName': 'Doxycycline Hyclate', 'tradeNames_list': "['Acticlate', 'Acticlate cap', 'Alodox', 'Atridox', 'Cyclodox', 'Demix 100Demix 50', 'Doryx', 'Doryx mpc', 'Doxatet', 'Doxy', 'Doxy 100', 'Doxy 200Doxy-Caps', 'Doxy-lemmon', 'Doxychel hyclate', 'Doxycycline hyclateDoxylar', 'Lymepak', 'Nordox', 'Periostat', 'Ramysis', 'Vibra-tabsVibramycin', 'Vibramycin 50', 'Vibramycin Hyclate', 'Vibramycin acne packVibramycin-d', 'Vibrox']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137745', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.859 | Q16 | What Small molecule therapies have been approved by the FDA to treat cannabis dependence? | There are no drug Small molecule therapies approved to treat cannabis dependence. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cannabis dependence" OR LOWER(mesh_heading) = "cannabis dependence") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.160 | Q16 | What Protein therapies have been approved by the FDA to treat familial lipoprotein lipase deficiency? | There are no drug Protein therapies approved to treat familial lipoprotein lipase deficiency. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial lipoprotein lipase deficiency" OR LOWER(mesh_heading) = "familial lipoprotein lipase deficiency") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.903 | Q16 | What Small molecule therapies have been approved by the FDA to treat chordoma? | There are no drug Small molecule therapies approved to treat chordoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chordoma" OR LOWER(mesh_heading) = "chordoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1390 | Q16 | What Small molecule therapies have been approved by the FDA to treat non-allergic rhinitis? | Aspirin is the only Small molecule therapy approved by the FDA to treat non-allergic rhinitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "non-allergic rhinitis" OR LOWER(mesh_heading) = "non-allergic rhinitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833653', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_833810', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_833967', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834124', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834281', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834438', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834595', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834752', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_834909', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835066', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835223', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835380', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835537', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835694', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_835851', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_836008', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'non-allergic rhinitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.259 | Q16 | What Protein therapies have been approved by the FDA to treat plasmacytoma? | There are no drug Protein therapies approved to treat plasmacytoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "plasmacytoma" OR LOWER(mesh_heading) = "plasmacytoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.337 | Q16 | What Small molecule therapies have been approved by the FDA to treat Alzheimer disease? | There are 2 Small molecule therapy drugs that are approved to treat Alzheimer disease which are as follows: Memantine Hydrochloride and Donepezil Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "alzheimer disease" OR LOWER(mesh_heading) = "alzheimer disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_454994', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455008', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455022', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455036', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455050', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455064', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455078', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455092', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000176884', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455106', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455120', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455134', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455148', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455162', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455176', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455190', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455204', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000183454', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455218', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455232', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455246', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455260', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455274', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455288', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455302', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455316', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000273079', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455330', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455344', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455358', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455372', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455386', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455400', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455414', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455428', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000105464', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455442', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455456', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455470', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455484', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455498', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455512', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455526', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455540', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000116032', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455554', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455568', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455582', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455596', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455610', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455624', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455638', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455652', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000161509', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455666', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455680', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455694', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455708', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455722', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455736', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455750', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_455764', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000198785', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993788', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993800', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993812', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993824', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993836', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993848', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993860', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993872', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993884', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993896', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993908', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993920', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993932', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993944', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}, {'UUID': 'DrugTargetsIndication121923_text_993956', 'drugName': 'Donepezil Hydrochloride', 'tradeNames_list': "['Adlarity', 'Aricept', 'Aricept evess', 'Aricept odtDonepezil hydrochloride']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000087085', 'approvedSymbol': 'ACHE', 'approvedName': 'acetylcholinesterase (Cartwright blood group)', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1654 | Q16 | What Small molecule therapies have been approved by the FDA to treat sprain? | There are 3 Small molecule therapy drugs that are approved to treat sprain which are as follows: Lidocaine, Diclofenac, and Capsaicin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "sprain" OR LOWER(mesh_heading) = "sprain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_637792', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_637907', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638022', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638137', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638252', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638367', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638482', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638597', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638712', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638827', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_638942', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639057', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639172', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639287', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639402', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639517', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639632', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639747', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639862', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_639977', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640092', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640207', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640322', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640437', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136546', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640552', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640667', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640782', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_640897', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641012', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641127', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000136531', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641242', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641357', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641472', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641587', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641702', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641817', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000169432', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_641932', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642047', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642162', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642277', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642392', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642507', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000153253', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642622', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642737', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642852', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_642967', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643082', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643197', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000168356', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643312', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643427', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643542', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643657', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643772', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_643887', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000196876', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644002', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644117', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644232', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644347', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644462', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_644577', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000185313', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_836982', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837012', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837042', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837072', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837102', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837132', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837162', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837192', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837222', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837252', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837282', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837312', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837342', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837372', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837402', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837432', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837462', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837492', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837522', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837552', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837582', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837612', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837642', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837672', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837702', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837732', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837762', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837792', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837822', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837852', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837882', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837912', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837942', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_837972', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_838002', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_838032', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_993044', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_993081', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_993118', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}, {'UUID': 'DrugTargetsIndication121923_text_993155', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sprains and Strains', 'efo_term': 'sprain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1047 | Q16 | What Small molecule therapies have been approved by the FDA to treat exfoliative dermatitis? | There are 2 Small molecule therapy drugs that are approved to treat exfoliative dermatitis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "exfoliative dermatitis" OR LOWER(mesh_heading) = "exfoliative dermatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217660', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_217868', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218076', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218284', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218492', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218700', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_218908', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219116', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219324', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219532', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219740', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_219948', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220156', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220364', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220572', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_220780', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226355', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226640', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_226925', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227210', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227495', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_227780', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228065', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228350', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228635', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_228920', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229205', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229490', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_229775', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230060', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230630', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_230915', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231200', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231485', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_231770', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232055', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}, {'UUID': 'DrugTargetsIndication121923_text_232340', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Exfoliative', 'efo_term': 'exfoliative dermatitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.519 | Q16 | What Small molecule therapies have been approved by the FDA to treat Ischemic stroke? | There are no drug Small molecule therapies approved to treat Ischemic stroke. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ischemic stroke" OR LOWER(mesh_heading) = "ischemic stroke") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1023 | Q16 | What Small molecule therapies have been approved by the FDA to treat endometriosis? | Elagolix Sodium is the only Small molecule therapy approved by the FDA to treat endometriosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "endometriosis" OR LOWER(mesh_heading) = "endometriosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097296', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097297', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097298', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097299', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097300', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097301', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097302', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097303', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097304', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}, {'UUID': 'DrugTargetsIndication121923_text_1097305', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000109163', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.776 | Q16 | What Small molecule therapies have been approved by the FDA to treat antiphospholipid syndrome? | There are no drug Small molecule therapies approved to treat antiphospholipid syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "antiphospholipid syndrome" OR LOWER(mesh_heading) = "antiphospholipid syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1539 | Q16 | What Small molecule therapies have been approved by the FDA to treat prostate carcinoma? | There are 7 Small molecule therapy drugs that are approved to treat prostate carcinoma which are as follows: Cabazitaxel, Lidocaine Hydrochloride, Enzalutamide, Apalutamide, Darolutamide, Abiraterone Acetate, and Zoledronic Acid. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostate carcinoma" OR LOWER(mesh_heading) = "prostate carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_67883', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67907', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67931', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67955', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_67979', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68003', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000188229', 'approvedSymbol': 'TUBB4B', 'approvedName': 'tubulin beta 4B class IVb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68027', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68051', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68075', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68099', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68123', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68147', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101162', 'approvedSymbol': 'TUBB1', 'approvedName': 'tubulin beta 1 class VI', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68171', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68195', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68219', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68243', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68267', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68291', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198033', 'approvedSymbol': 'TUBA3C', 'approvedName': 'tubulin alpha 3c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68315', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68339', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68363', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68387', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68411', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68435', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000127824', 'approvedSymbol': 'TUBA4A', 'approvedName': 'tubulin alpha 4a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68459', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68483', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68507', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68531', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68555', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68579', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000258947', 'approvedSymbol': 'TUBB3', 'approvedName': 'tubulin beta 3 class III', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68603', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68627', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68651', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68675', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68699', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68723', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167552', 'approvedSymbol': 'TUBA1A', 'approvedName': 'tubulin alpha 1a', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68747', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68771', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68795', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68819', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68843', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68867', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000104833', 'approvedSymbol': 'TUBB4A', 'approvedName': 'tubulin beta 4A class IVa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68891', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68915', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68939', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68963', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_68987', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69011', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000261456', 'approvedSymbol': 'TUBB8', 'approvedName': 'tubulin beta 8 class VIII', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69035', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69059', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69083', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69107', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69131', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69155', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196230', 'approvedSymbol': 'TUBB', 'approvedName': 'tubulin beta class I', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69179', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69203', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69227', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69251', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69275', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69299', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000123416', 'approvedSymbol': 'TUBA1B', 'approvedName': 'tubulin alpha 1b', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69323', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69347', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69371', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69395', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69419', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69443', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167553', 'approvedSymbol': 'TUBA1C', 'approvedName': 'tubulin alpha 1c', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69467', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69491', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69515', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69539', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69563', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69587', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000152086', 'approvedSymbol': 'TUBA3E', 'approvedName': 'tubulin alpha 3e', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69611', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69635', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69659', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69683', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69707', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69731', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137267', 'approvedSymbol': 'TUBB2A', 'approvedName': 'tubulin beta 2A class IIa', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69755', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69779', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69803', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69827', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69851', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69875', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000137285', 'approvedSymbol': 'TUBB2B', 'approvedName': 'tubulin beta 2B class IIb', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69899', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69923', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69947', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69971', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_69995', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_70019', 'drugName': 'Cabazitaxel', 'tradeNames_list': "['Jevtana', 'Jevtana kit']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176014', 'approvedSymbol': 'TUBB6', 'approvedName': 'tubulin beta 6 class V', 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_636908', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_636928', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_636948', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_636968', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000144285', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_636988', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_637008', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_637028', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_637048', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_637068', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}, {'UUID': 'DrugTargetsIndication121923_text_637088', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_list': "['Akten', 'Alphacaine hydrochloride', 'Anestacon', 'Anodesyn', 'BismodyneBradosol plus', 'Calgel', 'Co-phenylcaine fte', 'Denela', 'DequasprayEmla', 'Germoloids', 'Germoloids complete', 'Glydo', 'Hemocane', 'IgluInstillagel', 'Laryng-o-jet kit', 'LaryngojetLaryngotracheal anesthesia kit', 'Lido hcl', 'Lidocaine hydrochlorideLidocaine hydrochloride preservative freeLidocaine hydrochloride viscous', 'Lidocaine viscous', 'LidocatonLidopen', 'Lignokent', 'Lignospan special', 'Lignostab', 'Lignostab a 100Lignostab n', 'Lignostab-a', 'Lta ii kit', 'Medijel', 'OragardPediatric lta kit', 'Preparation h', 'Rexocaine', 'Versatis', 'XylocaineXylocaine dental', 'Xylocaine preservative free', 'Xylocaine viscousXylotox e80', 'Zingo']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.769 | Q16 | What Small molecule therapies have been approved by the FDA to treat ankylosing spondylitis? | There are 7 Small molecule therapy drugs that are approved to treat ankylosing spondylitis which are as follows: Prednisone, Dexamethasone, Indomethacin, Celecoxib, Naproxen Sodium, Naproxen, and Esomeprazole Magnesium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ankylosing spondylitis" OR LOWER(mesh_heading) = "ankylosing spondylitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217641', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_217849', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218057', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218265', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218473', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218681', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_218889', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219097', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219305', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219513', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219721', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_219929', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220137', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220345', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220553', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_220761', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226621', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_226906', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227191', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227476', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_227761', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228046', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_228901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_229756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230611', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_230896', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231181', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231466', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_231751', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_232036', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_232321', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828203', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828237', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828271', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828305', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828339', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828373', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828407', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828441', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828475', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828509', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828543', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_828577', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_832944', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833055', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833166', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833277', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833388', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_833499', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838048', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838065', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838082', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838099', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838116', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838133', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838150', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838167', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838184', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838201', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838218', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838235', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838252', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838269', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838286', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838303', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838335', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838376', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838417', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838458', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838499', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838540', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838581', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838622', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838663', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838704', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838745', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838786', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838827', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838868', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838909', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838950', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_838991', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839032', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839073', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839114', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839155', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839196', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839237', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839278', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839319', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839360', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839401', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}, {'UUID': 'DrugTargetsIndication121923_text_839442', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spondylitis, Ankylosing', 'efo_term': 'ankylosing spondylitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1212 | Q16 | What Small molecule therapies have been approved by the FDA to treat intracerebral hemorrhage? | There are no drug Small molecule therapies approved to treat intracerebral hemorrhage. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intracerebral hemorrhage" OR LOWER(mesh_heading) = "intracerebral hemorrhage") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1288 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant peritoneal mesothelioma? | Pemetrexed is the only Small molecule therapy approved by the FDA to treat malignant peritoneal mesothelioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant peritoneal mesothelioma" OR LOWER(mesh_heading) = "malignant peritoneal mesothelioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918481', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918544', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918607', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918670', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918733', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000176890', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918796', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918859', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918922', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_918985', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919048', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159131', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919111', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919174', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919237', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919300', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}, {'UUID': 'DrugTargetsIndication121923_text_919363', 'drugName': 'Pemetrexed', 'tradeNames_list': "['Alimta', 'Pemfexy']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000228716', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Mesothelioma', 'efo_term': 'malignant peritoneal mesothelioma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1747 | Q16 | What Small molecule therapies have been approved by the FDA to treat vasomotor rhinitis? | There are 2 Small molecule therapy drugs that are approved to treat vasomotor rhinitis which are as follows: Carbinoxamine Maleate and Azelastine Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "vasomotor rhinitis" OR LOWER(mesh_heading) = "vasomotor rhinitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455852', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455858', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455870', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455878', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455886', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455894', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455902', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455910', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455918', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455926', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455934', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455942', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}, {'UUID': 'DrugTargetsIndication121923_text_455950', 'drugName': 'Azelastine Hydrochloride', 'tradeNames_list': '[\'Astelin\', \'Astepro\', \'Astepro allergy\', "Azelastine hydrochlorideChildren\'s astepro allergyOptilast", \'Optivar\', \'RhinolastRhinolast allergy\']', 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000196639', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Vasomotor', 'efo_term': 'vasomotor rhinitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.525 | Q16 | What Small molecule therapies have been approved by the FDA to treat Kidney Angiomyolipoma? | Everolimus is the only Small molecule therapy approved by the FDA to treat Kidney Angiomyolipoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kidney angiomyolipoma" OR LOWER(mesh_heading) = "kidney angiomyolipoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084964', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085099', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085234', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085369', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085504', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085639', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085774', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1085909', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086044', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086179', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086314', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086449', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086584', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086719', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086854', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1086989', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087124', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087259', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087394', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087529', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087664', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087799', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1087934', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088069', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088204', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088339', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088474', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088609', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088744', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1088879', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089014', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089149', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089284', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089419', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089554', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089689', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089824', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1089959', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090094', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090229', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090364', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090499', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}, {'UUID': 'DrugTargetsIndication121923_text_1090634', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angiomyolipoma', 'efo_term': 'Kidney Angiomyolipoma'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.